Shares of the Map Pharmaceuticals took a huge leap after the announcement of success of its newly developed drug in last stage of human tests.

Map Pharmaceuticals Inc. announced that its migraine drug, Levadex caused no serious adverse events during tests on 792 people. A statistically significant number of patients reported pain relief 30 minutes after taking the drug.

Map's vice president of clinical development said: "If these findings are confirmed in a second phase 3 trial and Levadex is approved for marketing, Levadex could offer significant benefit to many of the 30 million migraine sufferers in the U. S., including many who are not helped by currently available migraine medications."